Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05493735 · ClinicalTrials.gov registry record · Phase 3

Lidocaine for Pessary Check Pain Reduction

A Phase 3 study of Pelvic Organ Prolapse and Stress Urinary Incontinence, sponsored by University of South Florida.

Completed
Registry status
Phase 3
Development phase
66
Enrollment target
1
Study location

NCT05493735 is a Phase 3 study of Pelvic Organ Prolapse and Stress Urinary Incontinence that has completed, run by University of South Florida. The registered enrollment target is 66 participants, below the 144-participant average among 40 other Pelvic Organ Prolapse trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05493735, a Phase 3 study of Pelvic Organ Prolapse and Stress Urinary Incontinence, has completed, sponsored by University of South Florida.

COMPLETED
Registry status
Phase 3
Development phase
66 participants
Enrollment target
1
Study location

Study Summary

The primary objective of this study is to estimate the effect of lidocaine jelly on patient pain at the time of office pessary removal.

Interventions

  • DRUG Lidocaine Hcl 2% Jelly
  • DRUG Placebo Jelly

Study Locations (1)

Florida

  • USF Health Outpatient Urogynecology Clinics - Tampa

Trial Details

FieldValue
Enrollment Target 66 participants
Start Date 2022-09-08
Est. Completion 2023-06-30
Phase Phase 3

Sponsor

University of South Florida

252 total trials

What the Registry Record Tells You About NCT05493735

The ClinicalTrials.gov registry entry for NCT05493735 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 144-participant average among 40 other Pelvic Organ Prolapse trials with a reported enrollment target (54% lower). The listed sponsor is University of South Florida, which has 252 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Pelvic Organ Prolapse appearing as the primary indexed condition, and to 2 interventions - of which Lidocaine Hcl 2% Jelly is the first listed.

NCT05493735 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT05493735 about?

NCT05493735 is a clinical study titled "Lidocaine for Pessary Check Pain Reduction". The primary objective of this study is to estimate the effect of lidocaine jelly on patient pain at the time of office pessary removal.

What is the current status of trial NCT05493735?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 66 participants. The study started on 2022-09-08. Estimated completion is 2023-06-30.

What conditions does trial NCT05493735 study?

This clinical trial studies the following conditions: Pelvic Organ Prolapse, Stress Urinary Incontinence.

What interventions are being tested in trial NCT05493735?

The interventions under investigation include: Lidocaine Hcl 2% Jelly (DRUG), Placebo Jelly (DRUG).

Who is sponsoring clinical trial NCT05493735?

This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05493735 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pelvic Organ Prolapse

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.